Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desobel
- Development stage
- Unknown
- Lead developer
- Effik
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DESOBEL is a third-generation combined oral hormonal contraceptive developed and marketed by the French pharmaceutical company Effik. It is composed of the progestin desogestrel (150 micrograms) and the estrogen ethinylestradiol, provided in two formulations containing either 20 micrograms (Desobel Gé 20) or 30 micrograms (Desobel Gé 30) of the estrogen component. The medication functions by suppressing the mid-cycle surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby inhibiting ovulation. Additionally, it induces changes in the cervical mucus to impede sperm penetration and alters the endometrium to reduce the likelihood of implantation. Desobel is indicated for the prevention of pregnancy in women and is notable for being the first low-dose third-generation pill to receive reimbursement in the French healthcare system.
- Brand names
- DesobelDesobel Gé 20Desobel Gé 30
- Other names
- desogestrel + ethinylestradiol
02
Targets
ESR1 (ERα)PR (Progesterone receptor)
Beyond the preview
Go deeper on Desobel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Desobel.